[
  {
    "ts": null,
    "headline": "ABEO: First Patient Treated with Zevaskyn速 Pushed to 4Q25 Following Assay Optimization",
    "summary": "By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update First Patient Treated with Zevaskyn速 Pushed to 4Q25 The first patient treated with Zevaskyn was pushed back to the fourth quarter of 2025 following the optimization of a release assay during the third quarter of 2025. A full batch of drug product was produced following biopsy collection from a patient in August",
    "url": "https://finnhub.io/api/news?id=85b700612a043e9a6ade7a2d13ff4b5b6f22e5bb52748ebe14a05e5b867b8fb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763107200,
      "headline": "ABEO: First Patient Treated with Zevaskyn速 Pushed to 4Q25 Following Assay Optimization",
      "id": 137480485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update First Patient Treated with Zevaskyn速 Pushed to 4Q25 The first patient treated with Zevaskyn was pushed back to the fourth quarter of 2025 following the optimization of a release assay during the third quarter of 2025. A full batch of drug product was produced following biopsy collection from a patient in August",
      "url": "https://finnhub.io/api/news?id=85b700612a043e9a6ade7a2d13ff4b5b6f22e5bb52748ebe14a05e5b867b8fb0"
    }
  }
]